Last reviewed · How we verify
GW823296 tablet
GW823296 tablet is a Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 1 development. Also known as: Orvepitant.
At a glance
| Generic name | GW823296 tablet |
|---|---|
| Also known as | Orvepitant |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GW823296 tablet CI brief — competitive landscape report
- GW823296 tablet updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GW823296 tablet
What is GW823296 tablet?
GW823296 tablet is a Small molecule drug developed by GlaxoSmithKline.
Who makes GW823296 tablet?
GW823296 tablet is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
Is GW823296 tablet also known as anything else?
GW823296 tablet is also known as Orvepitant.
What development phase is GW823296 tablet in?
GW823296 tablet is in Phase 1.
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Also known as: Orvepitant
- Compare: GW823296 tablet vs similar drugs
- Pricing: GW823296 tablet cost, discount & access